Publication | Closed Access

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

Health SciencesMedicinePotent Antitumor ActivityCancer GrowthImmune Checkpoint InhibitorPharmacotherapyAnti-cancer AgentCrizotinib ResistancePharmacologyRadiation OncologyDrug DiscoveryDrug Resistance